Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference2%

- Check29 days agoChange DetectedAppended version label (v3.1.0) and removal of multiple drug-safety related sections, indicating content consolidation and reorganization rather than new substantive content.SummaryDifference0.3%

- Check44 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.1%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.1%

- Check58 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations, as well as new topics related to drug safety and kidney cancer. The version has also been updated from v2.16.12 to v3.0.0.SummaryDifference5%

- Check72 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.